Tom Cohen

Merus’s Preclinical Bispecific Zeno Demonstrates Efficacy in Cancer Models

—

by

Tom Cohen
in

Zeno interrupts the dimerization of HER2 and HER3 and prevents NRG1/HER3 tumour signalling.

Read More

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *